Dec 17, 2003
Morgan Stanley Children's Hospital of NewYork-Presbyterian has selected Dr. William Treem, one of the foremost authorities in the treatment of pediatric liver disease and bowel disease, to be director of the newly created Division of Pediatric Gastroenterology, Hepatology and Nutrition. Additionally, Columbia University College of Physicians & Surgeons has appointed Dr. Treem as professor of Clinical Pediatrics.
"We are thrilled to welcome Dr. William Treem to Children's Hospital," said Dr. John Driscoll, Chairman of Pediatrics at Morgan Stanley Children's Hospital of NewYork Presbyterian. "Dr. Treem's many contributions include his discovery of an enzyme replacement treatment, which was approved by the FDA in 1999 for treatment of congenital sucrase isomaltase deficiency, a genetic disorder. He is an expert in inflammatory bowel disease, including the use of cyclosporin, an immunosuppressive drug, to treat fulminant ulcerative colitis, a life-threatening inflammatory condition. Dr. Treem authored one of the first papers on carnitine transport defect, a rare and life-threatening condition, and was one of the first to describe a link between acute fatty liver of pregnancy and a fatty acid oxidation disorder in the fetus, another rare but life-threatening condition in which the body is unable to breakdown fatty acids to make energy."
Dr. Treem graduated from Stanford University School of Medicine in 1977 and completed his residency at Boston's Children's Hospital in 1980. His previous clinical appointments include Concord Clinic in Concord, New Hampshire, Georgetown Medical Center, Philadelphia Children's Hospital, and University of Connecticut Hartford Hospital. Prior to accepting a position at Morgan Stanley Children's Hospital of NewYork-Presbyterian, Dr. Treem was affiliated with Duke University Medical Center, where he developed their distinguished pediatric gastroenterology program.
Dr. Treem has authored more than 80 original publications and 36 reviews, editorials, and textbook chapters. He has been awarded a number of grants during his academic career, including an FDA Orphan Drug Grant that supported research leading to the approval of Sucraid, a drug therapy for congenital sucrase-isomaltase deficiency.